FEBRUARY 18, 2012

Browse Categories

ASCO 2009 - Final Results of the Phase III, Randomized, Double-Blind AVOREN Trial of First-Line Bevacizumab + Interferon-α2a in Metastatic Renal Cell Carcinoma - Session Highlights

Wed, 03 June 2009
E-mail Print

ORLANDO, FL, USA (UroToday.com) - The authors reported the final results from the bevacizumab plus interferon vs. interferon alone trial for patients with metastatic renal cell carcinoma (mRCC).




Your session will expire in 8 hours requiring you to log in each day to view content.
Share |